Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : University Health Network
Deal Size : Undisclosed
Deal Type : Agreement
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
Details : The primary objective of the RCT is to evaluate oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 20, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : University Health Network
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Otenaproxesul
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Sun Pharma Subsidiary Taro Acquires Antibe Therapeutics
Details : Through the acquisition, Taro will leverage Antibe pipeline, including ATB-346 (otenaproxesul), a novel NSAID. It is being evaluated for the treatment of Osteoarthritis.
Product Name : ATB-346
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2025
Lead Product(s) : Otenaproxesul
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Raymond James & Associates, Inc.
Deal Size : $30.0 million
Deal Type : Public Offering
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approx $30 Million
Details : Eupraxia will use net proceeds to fund research activities, including EP-104IAR, a novel, sustained-release corticosteroid formulation for treating osteoarthritis.
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Undisclosed
November 03, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Raymond James & Associates, Inc.
Deal Size : $30.0 million
Deal Type : Public Offering
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Raymond James & Associates, Inc.
Deal Size : $33.9 million
Deal Type : Public Offering
Eupraxia Pharmaceuticals Closes Overnight Offering for Gross Proceeds Of C$33.9M
Details : The net proceeds will be used for developing EP-104IAR (fluticasone propionate), which is a GR-agonist. Currently, it is being evaluated in the Phase 2 clinical trial studies for Osteoarthritis.
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Undisclosed
March 15, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Raymond James & Associates, Inc.
Deal Size : $33.9 million
Deal Type : Public Offering
Lead Product(s) : Ginsenoside
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Redsenol-1 Plus Noble Ginsenoside Capsules, offers highly bioactive and absorbable rare ginsenoside monomers Rg3, Rh1, Rh2, Rk1, Rk3, Rg5, Rh3, Rh4, Rk2, aPPD, aPPT. Product is being investigated for treating cancer-related fatigue.
Product Name : Redsenol-1 Plus
Product Type : Steroid
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Ginsenoside
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EP-104AR (fluticasone propionate) endeavours to provide long-term pain relief with fewer unwanted side effects for Osteoarthritis patients It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane and ...
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Inapplicable
June 26, 2023
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FSD201 (palmitoylethanolamide) with enhanced anti-inflammatory properties, it is a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy making it suitable to treat a range of inflammatory conditions
Product Name : FSD201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR
Details : EP-104IAR is composed of fluticasone propionate drug crystals coated with heat-treated polyvinyl alcohol (PVA) to result in extended release properties used in knee osteoarthritis pain.
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Otenaproxesul
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Veristat
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin.
Product Name : ATB-346
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : Otenaproxesul
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Veristat
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Otenaproxesul
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antibe Therapeutics Provides Clinical Update for Otenaproxesul
Details : The AME study had enrolled a total of 42 subjects on either a 75 mg or 100 mg daily dose of otenaproxesul, of whom 35 had completed the 28-day drug administration period, with seven subjects having been administered the drug for 21 days.
Product Name : ATB-346
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : Otenaproxesul
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable